{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:10Z","timestamp":1787962270247,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1136\/ard.2005.038349","type":"journal-article","created":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T01:34:54Z","timestamp":1142472894000},"page":"1578-1584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs"],"prefix":"10.1016","volume":"65","author":[{"given":"L","family":"Klareskog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rodriguez-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Malaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wajdula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.038349_bib1","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [comment] [erratum appears in N Engl J Med 2001;344:240]","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.038349_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.038349_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2005.038349_bib4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2005.038349_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [comment]","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.038349_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib8","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973\u20131999) [11 Registries, 1992\u20131999)]. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission."},{"key":"10.1136\/ard.2005.038349_bib9","first-page":"1232","article-title":"Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib10","first-page":"1238","article-title":"Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/ard.51.12.1318","article-title":"Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis","volume":"51","author":"Morand","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.038349_bib12","first-page":"994","article-title":"Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/art.11015","article-title":"The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study","volume":"48","author":"Kalden","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib14","first-page":"FRI0050","article-title":"A long-term open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis) [abstract]","volume":"61","author":"Klareskog","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.038349_bib15","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.4049\/jimmunol.143.9.2894","article-title":"Evidence that tumor necrosis factor has an important role in antibacterial resistance","volume":"143","author":"Havell","year":"1989","journal-title":"J Immunol"},{"key":"10.1136\/ard.2005.038349_bib16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1136\/ard.2005.038349_bib17","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1128\/iai.64.12.5211-5218.1996","article-title":"Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia","volume":"64","author":"Laichalk","year":"1996","journal-title":"Infect Immun"},{"key":"10.1136\/ard.2005.038349_bib18","first-page":"2857","article-title":"Postlicensure reports of infection during use of etanercept and infliximab","volume":"43","author":"Gershon","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard.2005.038349_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(85)90246-3","article-title":"Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort","volume":"78","author":"Katusic","year":"1985","journal-title":"Am J Med"},{"key":"10.1136\/ard.2005.038349_bib21","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","article-title":"No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis","volume":"41","author":"van den Borne","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.038349_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.23.3.193","article-title":"Course and prognosis in rheumatoid arthritis: a further report","volume":"23","author":"Duthie","year":"1964","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.038349_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/rheumatology\/23.2.92","article-title":"Cause of death in rheumatoid arthritis","volume":"23","author":"Prior","year":"1984","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib26","first-page":"1942","article-title":"Infections in rheumatoid arthritis\u00e2\u20ac\u201da new phenomenon?","volume":"28","author":"Doran","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib27","first-page":"2529","article-title":"Mortality in rheumatoid arthritis: have we made an impact in 4 decades? [see comments]","volume":"26","author":"Gabriel","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.038349_bib28","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1136\/ard.2005.038349_bib29","first-page":"S78","article-title":"Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA trial): observations at 3 years [abstract]","volume":"44","author":"Genovese","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.038349_bib30","first-page":"231","article-title":"Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manage Care"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724199499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724199499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.038349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:23:56Z","timestamp":1736087036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724199499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0003496724199499"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.038349","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.038349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}